journal article·2019-06-25

Polymer-Coated Gold Nanospheres Do Not Impair the Innate Immune Function of Human B Lymphocytes in Vitro

Sandra Hočevar, Ana Milošević, Laura Rodriguez-Lorenzo, Liliane Ackermann-Hirschi, Ines Mottas, Alke Petri-Fink, Barbara Rothen-Rutishauser, Carole Bourquin, Martin James David Clift

ACS Nano· Volume 13· Issue 6
Publisher page

Abstract

Gold nanoparticles (GNPs) are intended for use within a variety of biomedical applications due to their physicochemical properties. Although, in general, biocompatibility of GNPs with immune cells such as macrophages and dendritic cells is well established, the impact of GNPs on B lymphocyte immune function remains to be determined. Since B lymphocytes play an important role in health and disease, the suitability of GNPs as a B cell-targeting tool is of high relevance. Thus, we provide information on the interactions of GNPs with B lymphocytes. Herein, we exposed freshly isolated human B lymphocytes to a set of well-characterized and biomedically relevant GNPs with distinct surface (polyethylene glycol (PEG), PEG/poly(vinyl alcohol) (PEG/PVA)) and shape (spheres, rods) characteristics. Polymer-coated GNPs poorly interacted with B lymphocytes, in contrast to uncoated GNPs. Importantly, none of the GNPs significantly affected cell viability, even at the highest concentration of 20 μg/mL over a 24 h suspension exposure period. Furthermore, none of the nanosphere formulations affected the expression of activation markers (CD69, CD86, MHC II) of the naive B lymphocytes, nor did they cause an increase in the secretion of pro-inflammatory cytokines ( i.e. , IL-6, IL-1β). However, the absence of polymer coating on the sphere GNPs and the rod shape caused a decrease in IL-6 cytokine production by activated B lymphocytes, suggesting a functional impairment. With these findings, the present study contributes imperative knowledge toward the safe-by-design approaches being conducted to benefit the development of nanomaterials, specifically those as theranostic tools.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Extracellular vesicles in disease · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

BioNanomaterials, Adolphe Merkle Institute, University of Fribourg, 1700 Fribourg, Switzerland

School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1211 Geneva, Switzerland

Chair of Pharmacology, Faculty of Science and Medicine, University of Fribourg, 1700 Fribourg, Switzerland

Faculty of Medicine, University of Geneva, Rue Michel-Servet 1, 1211 Geneva, Switzerland

In Vitro Toxicology Group, Swansea University Medical School, Wales SA2 8PP, U.K.

Funding

Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung · Adolphe Merkle Foundation

References (63)

Show source-provided references
1. 10.1182/blood-2008-02-07807110.1182/blood-2008-02-078071 ↗
2. 10.1084/jem.2017145010.1084/jem.20171450 ↗
3. 10.1002/adma.20160694410.1002/adma.201606944 ↗
4. 10.1016/j.jaci.2018.01.00510.1016/j.jaci.2018.01.005 ↗
5. 10.1038/cmi.2012.6110.1038/cmi.2012.61 ↗
6. 10.1016/j.smim.2017.08.01310.1016/j.smim.2017.08.013 ↗
7. 10.1016/j.tox.2014.03.00810.1016/j.tox.2014.03.008 ↗
8. 10.1039/C3NR05772K10.1039/C3NR05772K ↗
9. 10.1007/s00011-016-0919-010.1007/s00011-016-0919-0 ↗
10. 10.1002/med.2140310.1002/med.21403 ↗
11. 10.2903/j.efsa.2013.330310.2903/j.efsa.2013.3303 ↗
12. 10.1007/s11095-016-1961-x10.1007/s11095-016-1961-x ↗
13. 10.1039/C1CS15166E10.1039/C1CS15166E ↗
14. 10.1016/j.nano.2017.11.00910.1016/j.nano.2017.11.009 ↗
15. 10.1016/j.jconrel.2018.02.00410.1016/j.jconrel.2018.02.004 ↗
16. 10.1002/smll.20130288910.1002/smll.201302889 ↗
17. 10.1039/C6NR03543D10.1039/C6NR03543D ↗
18. 10.1021/acsnano.7b0204410.1021/acsnano.7b02044 ↗
19. 10.1021/es100417s10.1021/es100417s ↗
20. 10.1038/s41598-017-18502-810.1038/s41598-017-18502-8 ↗
21. 10.1039/c3ra22727h10.1039/c3ra22727h ↗
22. 10.1016/j.nano.2008.08.00110.1016/j.nano.2008.08.001 ↗
23. 10.1021/acs.bioconjchem.6b0057510.1021/acs.bioconjchem.6b00575 ↗
24. 10.1002/ppsc.20170041810.1002/ppsc.201700418 ↗
25. 10.1007/s13404-011-0015-810.1007/s13404-011-0015-8 ↗
26. 10.1039/C3RA22739A10.1039/C3RA22739A ↗
27. 10.1021/acs.langmuir.6b0128910.1021/acs.langmuir.6b01289 ↗
28. 10.1016/j.jcis.2017.06.10110.1016/j.jcis.2017.06.101 ↗
29. 10.1002/anie.20120856810.1002/anie.201208568 ↗
30. 10.1016/j.biomaterials.2010.01.06510.1016/j.biomaterials.2010.01.065 ↗
31. 10.1021/bm101482r10.1021/bm101482r ↗
32. 10.1007/s00216-016-9678-610.1007/s00216-016-9678-6 ↗
33. 10.1016/j.biocel.2015.11.00510.1016/j.biocel.2015.11.005 ↗
34. 10.1039/C6NR08194K10.1039/C6NR08194K ↗
35. 10.1007/s11051-009-9692-010.1007/s11051-009-9692-0 ↗
36. 10.1016/j.nano.2014.11.00410.1016/j.nano.2014.11.004 ↗
37. 10.1111/j.1365-2249.2010.04206.x10.1111/j.1365-2249.2010.04206.x ↗
38. 10.1006/cimm.2001.176910.1006/cimm.2001.1769 ↗
39. 10.4049/jimmunol.080225710.4049/jimmunol.0802257 ↗
40. 10.4049/jimmunol.080283110.4049/jimmunol.0802831 ↗
41. 10.1016/j.nantod.2015.06.00610.1016/j.nantod.2015.06.006 ↗
42. 10.1002/cyto.a.2092710.1002/cyto.a.20927 ↗
43. 10.4155/bio.11.16310.4155/bio.11.163 ↗
44. 10.1039/c3nr30071d10.1039/c3nr30071d ↗
45. 10.1088/0957-4484/25/12/12510310.1088/0957-4484/25/12/125103 ↗
46. 10.1111/j.1365-2567.2009.03143.x10.1111/j.1365-2567.2009.03143.x ↗
47. 10.1016/j.intimp.2011.05.01410.1016/j.intimp.2011.05.014 ↗
48. 10.1016/j.smim.2017.09.00310.1016/j.smim.2017.09.003 ↗
49. 10.1016/j.imbio.2015.12.00310.1016/j.imbio.2015.12.003 ↗
50. 10.1021/acs.langmuir.7b0185110.1021/acs.langmuir.7b01851 ↗
51. 10.1016/j.immuni.2018.08.01210.1016/j.immuni.2018.08.012 ↗
52. 10.1039/C5RA16164A10.1039/C5RA16164A ↗
53. 10.1186/1477-3155-11-2610.1186/1477-3155-11-26 ↗
54. 10.1021/nn405830g10.1021/nn405830g ↗
55. Food and Drug Admistration (FDA). Drug Products, Including Biological Products, that Contain Nanomaterials - Guidance for Industry. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM588857.pdf (accessed Sep 10, 2018).
56. 10.1039/df951110005510.1039/df9511100055 ↗
57. 10.1088/0957-4484/21/28/28510610.1088/0957-4484/21/28/285106 ↗
58. 10.1038/srep0979310.1038/srep09793 ↗
59. 10.1039/C6NR03386E10.1039/C6NR03386E ↗
60. 10.1063/1.365296710.1063/1.3652967 ↗
61. Technologies Inc. S. Frequencies Cell Types Human Peripheral Blood. https://www.stemcell.com/media/files/wallchart/WA10006-Frequencies_Cell_Types_Human_Peripheral_Blood.pdf (accessed Sep 10, 2018).
62. 10.1016/j.toxlet.2012.08.02610.1016/j.toxlet.2012.08.026 ↗
63. U.S. Food & Drug Administration. Elemental Analysis Manual (EAM) for Food and Related Products. http://www.fda.gov/EAM (accessed May 18, 2017).